Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension.

BACKGROUND To test the prognostic value of plasma renin activity prospectively, we determined the pretreatment renin-sodium profile of 1717 subjects with mild-to-moderate hypertension (mean age, 53 years; 36 percent white; 67 percent men) in a systematic work-site treatment program. METHODS Renin profiles, obtained by plotting plasma renin activity against the urinary excretion of sodium, were classified as high (12 percent of the subjects), normal (56 percent), and low (32 percent), and there were expected variations according to age, sex, and race. Modified stepped-care treatment for hypertension, prescribed without reference to the renin profile, was similar in the three renin groups. RESULTS Mean (+/- SD) blood pressure at entry was 151 +/- 19/100 +/- 10 mm Hg in the subjects with a high renin profile, 151 +/- 19/97 +/- 10 mm Hg in those with a normal profile, and 151 +/- 20/96 +/- 11 mm Hg in those with a low profile. During 8.3 years of follow-up, there were 27 myocardial infarctions. As adjusted for age, sex, and race, the incidence of myocardial infarction per 1000 person-years was 14.7 among the subjects with a high renin profile, 5.6 among those with a normal profile, and 2.8 among those with a low profile (rate ratio for high vs. low, 5.3; 95 percent confidence interval, 3.4 to 8.3). The rate of mortality from all causes was 9.3 in the high-profile group, 5.3 in the normal-profile group, and 3.9 in the low-profile group. The independent association of a high renin profile with myocardial infarction (but not with stroke or noncardiovascular events) was affirmed by Cox analyses (rate ratio for high vs. normal plus low, 3.2; 95 percent confidence interval, 1.2 to 8.4) after adjustment for race, sex, age at entry, serum cholesterol level, smoking status, electrocardiographic evidence of left ventricular hypertrophy, blood glucose level, body-mass index, history of cardiovascular disease or treatment, blood pressure, and use of beta-blockers. CONCLUSIONS In the study population, whose blood pressure before and during treatment was in a narrow range, and after other cardiovascular risk factors had been considered, the renin profile before treatment remained independently associated with the subsequent risk of myocardial infarction.

[1]  H. Baumgartner,et al.  Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury. , 1989, Science.

[2]  J. Laragh,et al.  On the renal basis for essential hypertension: nephron heterogeneity with discordant renin secretion and sodium excretion causing a hypertensive vasoconstriction-volume relationship. , 1988, Journal of hypertension.

[3]  R. Peto,et al.  Beta blockade during and after myocardial infarction: an overview of the randomized trials. , 1985, Progress in cardiovascular diseases.

[4]  T. Meade,et al.  The epidemiology of plasma renin. , 1983, Clinical science.

[5]  J. Sealey Measurement of the hormones of the renin system in hypertensive patients. , 1981, Clinical biochemistry.

[6]  J. Laragh,et al.  Prorenin and other large molecular weight forms of renin. , 1980, Endocrine reviews.

[7]  M. Alderman,et al.  Hypertension control at the work site. , 1976, Journal of occupational medicine. : official publication of the Industrial Medical Association.

[8]  R Shapiro,et al.  Interference by 2, 3-dimercapto-1-propanol (BAL) in angiotensin I radioimmunoassay. , 1976, The Journal of laboratory and clinical medicine.

[9]  C. Gomez-Sanchez,et al.  The intravenous furosemide test: a simple way to evaluate renin responsiveness. , 1976, Annals of internal medicine.

[10]  M. Alderman,et al.  Detection and treatment of hypertension at the work site. , 1975, The New England journal of medicine.

[11]  J. Laragh Vasoconstriction-volume analysis for understanding and treating hypertension: the use of renin and aldosterone profiles. , 1973, The American journal of medicine.

[12]  J. Laragh,et al.  Renin as a risk factor in essential hypertension: more evidence. , 1973, The American journal of medicine.

[13]  E. Freis Age, race, sex and other indices of risk in hypertension. , 1973, The American journal of medicine.

[14]  J. Laragh,et al.  Propranolol inhibition of renin secretion. A specific approach to diagnosis and treatment of renin-dependent hypertensive diseases. , 1972, The New England journal of medicine.

[15]  J. Laragh,et al.  Renin, angiotensin and aldosterone system in pathogenesis and management of hypertensive vascular disease. , 1972, The American journal of medicine.

[16]  J. Laragh,et al.  Essential hypertension: renin and aldosterone, heart attack and stroke. , 1972, The New England journal of medicine.

[17]  J. Brown,et al.  Acute renal failure, tubular necrosis, and myocardial infarction induced in the rabbit by intravenous angiotensin II. , 1971, Lancet.

[18]  J. Laragh The role of aldosterone in man. Evidence for regulation of electrolyte balance and arterial pressure by a renal-adrenal system which may be involved in malignant hypertension. , 1960, JAMA.

[19]  M. Winternitz,et al.  Studies on the Relation of the Kidney to Cardiovascular Disease , 1942, The Yale journal of biology and medicine.